Clinical trial NCT06607471: Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Official title: Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Non-ischemic Cardiomyopathy
Dilated Cardiomyopathy (DCM)
Hypertrophic Cardiomyopathy (HCM)
Restrictive Cardiomyopathy
Arrhythmogenic Cardiomyopathy (AC, ARVD/C)
Left Ventricular Noncompaction
Arrhythmogenic Mitral Valve Prolapse
Peripartum Cardiomyopathy
Anderson-Fabry Disease
Arrhythmic and Inflammatory Non-ischemic Cardiomyopathy
Inflammatory (Non-Arrhythmic) Non-ischemic Cardiomyopathy
Nonischemic Cardiomyopathy Sensu Strictu (Non-inflammatory, Non-arrhythmic)
Major Ventricular Arrhythmias, I.e. Sustained Ventricular Tachycardia, Ventricular Fibrillation, or Appropriate Therapy of Cardiac Device (defibrillators)
Overlapping Phenotype
Undefined Phenotypes
Keywords: Arrhythmogenic cardiomyopathy
Adverse event
Anderson-Fabry disease
Arrhythmic and Inflammatory Non-ischemic cardiomyopathy
Arrhythmogenic mitral valve prolapse
Anti tachycardia pacing
Bradiarrhythmias
Cardiac magnetic resonance
Cardiac resynchronization therapy with defibrillator
Computed tomography
Development Safety Update Report
Ethics Committee
Electroanatomical map
Electrocardiogram
Endomyocardial biopsy
Good Clinical Practice
Hypertrophic cardiomyopathy
Implantable cardioverter defibrillator
Informed Consent Form
International Conference on Harmonization
Immunomodulatory therapy
Late gadolinium enhancement
Left ventricular ejection fraction
Left ventricular noncompaction
Last Visit of Last Subject
Myocardial inflammation
Non-ischemic cardiomyopathies
Positron emission tomography
Pacemaker
Peripartum cardiomyopathy
Premature ventricular complexes
Serious Adverse Event
Supraventricular arrhythmias
Ventricular arrhythmias
Ventricular fibrillation
Ventricular tachycardia (sustained)
sudden cardiac death
Lead sponsor: Scientific Institute San Raffaele
Sponsor class: OTHER
First posted: 2024-09-23
Enrollment: 15000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is an international registry. Enrolment of NICM patients will be performed without restrictions concerning age, gender, ethnicity, social, political, or economical status. Both inpatients and outpatients will be suitable for enrollment. Beyond clinically suspected or proven NICMs, genotype-positive familial cases will be enrolled. The expected sample size is 150000, of whom 5000 will be enrolled at San Raffaele Hospital.

Brief summary: Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are "overlap" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the "undefined" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.

To the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and "inflammatory" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:

1. Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.
2. Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.

Based on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.

Detailed description: This study aims to collect clinical data of both retrospective and prospective patients with suspected or proven NICMs in a registry. The scope of the registry is to answer multiple unsolved questions in the field of AINICM as described below:

1. Improving the diagnostic workup. While genetic test and cardiac magnetic resonance (CMR) constitute the gold standard dagnostic techniques for NICM, it is known that; A) the yield of genetic test is low in NICM; B) the diagnostic performance of CMR may be limited in AINICM, because of cardiac device-related artifacts and/or irregular heartbeat. In this setting, alternative diagnostic techniques, namely computed tomography (CT) scan, positron emission tomography (PET), electroanatomical map (EAM) and endomyocardial biopsy (EMB) may be clinically helpful, as recommended for the investigation of many arrhythmogenic substrates.
2. Identifying disease-specific signatures. Genotype-phenoype associations are expected to benefit from a multimodal and multiparametric approach, in order to allow etiology-specific features in AINICM. Most of the current signatures are limited to combined genotype-CMR studies. Signatures would likely benefit from implementing additional parameters, including arrhythmia features and myocadial inflammatory status.
3. Working our models for risk prediction. Outcomes and arrhythmic risk stratification remain uncertain for most NICM. Based on an advanced multimodal workup, multiparametric risk scores may be created and subsequenlty validated, in order to predict the arrhythmic risk of specific cardiomyopathies. This would improve and refine the scores currently available for a limited number of NICM, such as HCM, classic right ventricular ACM, or cardiomyopathies secondary to LMNA gene mutation. Parameters from clinical arrhythmology and cardiac electrophysiology, as well as those related to inflammation, may improve the current status of the art about risk prediction.
4. Tailoring treatment strategies. A multimodal (i.e. by use of multiple diagnostic techniques) and multidisciplinary (i.e. by means of a team of cardiac electrophysiologists, cardiologists, radiologists, geneticists, immunologists, cardiac pathologists, pediatricians) model may help improving therapeutic strategies in AINICM, as already demonstrated in myocarditis. In detail, treatment options will include guideline-directed cardiological treatment, implantable cardiac devices, antiarrhythmic drugs, immunomodulating agents and catheter ablation of arrhythmias. In this setting, the coordinating center is an internationally recognized third-level referral center for the management of ventricular arrhythmias, and already has advanced facilities, including a dedicated multidisciplinary disease unit for myocarditis and inflammatory cardiomyopathies. In this setting, preliminary evidence suggests a potential benefit from targeting M-Infl even in NICM and AINICM.
5. Allowing direct comparison among specific NICM subgroups. Extensive inclusion criteria, allowing the entry of all NICM in a common registry with homogeneous variables would enable the direct comparison of different AINICM types, by means of multiparametric and multimodal characterization, for the first time including both the electrophysiological and inflammatory viewpoints. This is expected to significantly advance the status of knowledge in the field of NICM.

Eligibility criteria: Inclusion Criteria:

* Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.
* Clinical suspicion of NICM, and/or proven diagnosis of any NICM and/or genotype consistent with any NICM.

NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

Exclusion Criteria:

* Absent informed consent.
* Proven diagnosis of cardiac disease alternative to NICM.
* Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.
* For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.

Primary outcomes:
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
timeFrame: At year 30
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
timeFrame: At baseline
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
timeFrame: At year 5
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
timeFrame: At year 10
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
timeFrame: At year 15
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
timeFrame: At year 20
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
timeFrame: At year 25
measure: Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At baseline
measure: Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 5
measure: Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 10
measure: Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 15
measure: Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 20
measure: Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 25
measure: Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
timeFrame: At year 30
measure: Identification of DCM-specific signatures
timeFrame: At baseline
measure: Identification of DCM-specific signatures
timeFrame: At year 5
measure: Identification of DCM-specific signatures
timeFrame: At year 10
measure: Identification of DCM-specific signatures
timeFrame: At year 15
measure: Identification of DCM-specific signatures
timeFrame: At year 20
measure: Identification of DCM-specific signatures
timeFrame: At year 25
measure: Identification of DCM-specific signatures
timeFrame: At year 30
measure: Identification of HCM-specific signatures
timeFrame: At baseline
measure: Identification of HCM-specific signatures
timeFrame: At year 5
measure: Identification of HCM-specific signatures
timeFrame: At year 10
measure: Identification of HCM-specific signatures
timeFrame: At year 15
measure: Identification of HCM-specific signatures
timeFrame: At year 20
measure: Identification of HCM-specific signatures
timeFrame: At year 25
measure: Identification of HCM-specific signatures
timeFrame: At year 30
measure: Identification of RCM-specific signatures
timeFrame: At baseline
measure: Identification of RCM-specific signatures
timeFrame: At year 5
measure: Identification of RCM-specific signatures
timeFrame: At year 10
measure: Identification of RCM-specific signatures
timeFrame: At year 15
measure: Identification of RCM-specific signatures
timeFrame: At year 20
measure: Identification of RCM-specific signatures
timeFrame: At year 25
measure: Identification of RCM-specific signatures
timeFrame: At year 30
measure: Identification of ACM-specific signatures
timeFrame: At baseline
measure: Identification of ACM-specific signatures
timeFrame: At year 5
measure: Identification of ACM-specific signatures
timeFrame: At year 10
measure: Identification of ACM-specific signatures
timeFrame: At year 15
measure: Identification of ACM-specific signatures
timeFrame: At year 20
measure: Identification of ACM-specific signatures
timeFrame: At year 25
measure: Identification of ACM-specific signatures
timeFrame: At year 30
measure: Identification of LVNC-specific signatures
timeFrame: At baseline
measure: Identification of LVNC-specific signatures
timeFrame: At year 5
measure: Identification of LVNC-specific signatures
timeFrame: At year 10
measure: Identification of LVNC-specific signatures
timeFrame: At year 15
measure: Identification of LVNC-specific signatures
timeFrame: At year 20
measure: Identification of LVNC-specific signatures
timeFrame: At year 25
measure: Identification of LVNC-specific signatures
timeFrame: At year 30
measure: Identification of AMVP-specific signatures
timeFrame: At baseline
measure: Identification of AMVP-specific signatures
timeFrame: At year 5
measure: Identification of AMVP-specific signatures
timeFrame: At year 10
measure: Identification of AMVP-specific signatures
timeFrame: At year 15
measure: Identification of AMVP-specific signatures
timeFrame: At year 20
measure: Identification of AMVP-specific signatures
timeFrame: At year 25
measure: Identification of AMVP-specific signatures
timeFrame: At year 30
measure: Identification of PPCM-specific signatures
timeFrame: At baseline
measure: Identification of PPCM-specific signatures
timeFrame: At year 5
measure: Identification of PPCM-specific signatures
timeFrame: At year 10
measure: Identification of PPCM-specific signatures
timeFrame: At year 15
measure: Identification of PPCM-specific signatures
timeFrame: At year 20
measure: Identification of PPCM-specific signatures
timeFrame: At year 25
measure: Identification of PPCM-specific signatures
timeFrame: At year 30
measure: Identification of AFD-specific signatures
timeFrame: At baseline
measure: Identification of AFD-specific signatures
timeFrame: At year 5
measure: Identification of AFD-specific signatures
timeFrame: At year 10
measure: Identification of AFD-specific signatures
timeFrame: At year 15
measure: Identification of AFD-specific signatures
timeFrame: At year 20
measure: Identification of AFD-specific signatures
timeFrame: At year 25
measure: Identification of AFD-specific signatures
timeFrame: At year 30
measure: Identification of storage and dysmetabolic diseases-specific signatures
timeFrame: At baseline
measure: Identification of storage and dysmetabolic diseases-specific signatures
timeFrame: At year 5
measure: Identification of storage and dysmetabolic diseases-specific signatures
timeFrame: At year 10
measure: Identification of storage and dysmetabolic diseases-specific signatures
timeFrame: At year 15
measure: Identification of storage and dysmetabolic diseases-specific signatures
timeFrame: At year 20
measure: Identification of storage and dysmetabolic diseases-specific signatures
timeFrame: At year 25
measure: Identification of storage and dysmetabolic diseases-specific signatures
timeFrame: At year 30
measure: Identification of mitochondrial diseases-specific signatures
timeFrame: At baseline
measure: Identification of mitochondrial diseases-specific signatures
timeFrame: At year 5
measure: Identification of mitochondrial diseases-specific signatures
timeFrame: At year 10
measure: Identification of mitochondrial diseases-specific signatures
timeFrame: At year 15
measure: Identification of mitochondrial diseases-specific signatures
timeFrame: At year 20
measure: Identification of mitochondrial diseases-specific signatures
timeFrame: At year 25
measure: Identification of mitochondrial diseases-specific signatures
timeFrame: At year 30
measure: Identification of channelopathies with structural changes-specific signatures
timeFrame: At baseline
measure: Identification of channelopathies with structural changes-specific signatures
timeFrame: At year 5
measure: Identification of channelopathies with structural changes-specific signatures
timeFrame: At year 10
measure: Identification of channelopathies with structural changes-specific signatures
timeFrame: At year 15
measure: Identification of channelopathies with structural changes-specific signatures
timeFrame: At year 20
measure: Identification of channelopathies with structural changes-specific signatures
timeFrame: At year 25
measure: Identification of channelopathies with structural changes-specific signatures
timeFrame: At year 30
measure: Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
timeFrame: At baseline
measure: Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
timeFrame: At year 5
measure: Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
timeFrame: At year 10
measure: Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
timeFrame: At year 15
measure: Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
timeFrame: At year 20
measure: Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
timeFrame: At year 25
measure: Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
timeFrame: At year 30
measure: Identification of overlapping phenotypes-specific signatures
timeFrame: At baseline
measure: Identification of overlapping phenotypes-specific signatures
timeFrame: At year 5
measure: Identification of overlapping phenotypes-specific signatures
timeFrame: At year 10
measure: Identification of overlapping phenotypes-specific signatures
timeFrame: At year 15
measure: Identification of overlapping phenotypes-specific signatures
timeFrame: At year 20
measure: Identification of overlapping phenotypes-specific signatures
timeFrame: At year 25
measure: Identification of overlapping phenotypes-specific signatures
timeFrame: At year 30
measure: Identification of undefined phenotypes-specific signatures
timeFrame: At baseline
measure: Identification of undefined phenotypes-specific signatures
timeFrame: At year 5
measure: Identification of undefined phenotypes-specific signatures
timeFrame: At year 10
measure: Identification of undefined phenotypes-specific signatures
timeFrame: At year 15
measure: Identification of undefined phenotypes-specific signatures
timeFrame: At year 20
measure: Identification of undefined phenotypes-specific signatures
timeFrame: At year 25
measure: Identification of undefined phenotypes-specific signatures
timeFrame: At year 30
measure: Differences in incidence of major events during follow-up in different NICMs
timeFrame: At baseline
measure: Differences in incidence of major events during follow-up in different NICMs
timeFrame: At year 5
measure: Differences in incidence of major events during follow-up in different NICMs
timeFrame: At year 10
measure: Differences in incidence of major events during follow-up in different NICMs
timeFrame: At year 15
measure: Differences in incidence of major events during follow-up in different NICMs
timeFrame: At year 20
measure: Differences in incidence of major events during follow-up in different NICMs
timeFrame: At year 25
measure: Differences in incidence of major events during follow-up in different NICMs
timeFrame: At year 30
measure: Occurrence of major cardiac events in DCM
timeFrame: At 10 years
measure: Occurrence of major cardiac events in DCM
timeFrame: At 1 year
measure: Occurrence of major cardiac events in DCM
timeFrame: At 3 years
measure: Occurrence of major cardiac events in DCM
timeFrame: At 5 years
measure: Occurrence of major cardiac events in DCM
timeFrame: At 15 years
measure: Occurrence of major cardiac events in DCM
timeFrame: At 20 years
measure: Occurrence of major cardiac events in DCM
timeFrame: At 25 years
measure: Occurrence of major cardiac events in DCM
timeFrame: At 30 years
measure: Occurrence of major cardiac events in HCM
timeFrame: At 1 year
measure: Occurrence of major cardiac events in HCM
timeFrame: At 3 years
measure: Occurrence of major cardiac events in HCM
timeFrame: At 5 years
measure: Occurrence of major cardiac events in HCM
timeFrame: At 10 years
measure: Occurrence of major cardiac events in HCM
timeFrame: At 15 years
measure: Occurrence of major cardiac events in HCM
timeFrame: At 20 years
measure: Occurrence of major cardiac events in HCM
timeFrame: At 25 years
measure: Occurrence of major cardiac events in HCM
timeFrame: At 30 years
measure: Occurrence of major cardiac events in RCM
timeFrame: At 1 year
measure: Occurrence of major cardiac events in RCM
timeFrame: At 3 years
measure: Occurrence of major cardiac events in RCM
timeFrame: At 5 years
measure: Occurrence of major cardiac events in RCM
timeFrame: At 10 years
measure: Occurrence of major cardiac events in RCM
timeFrame: At 15 years
measure: Occurrence of major cardiac events in RCM
timeFrame: At 20 years
measure: Occurrence of major cardiac events in RCM
timeFrame: At 25 years
measure: Occurrence of major cardiac events in RCM
timeFrame: At 30 years
measure: Occurrence of major cardiac events in ACM
timeFrame: At 1 year
measure: Occurrence of major cardiac events in ACM
timeFrame: At 3 years
measure: Occurrence of major cardiac events in ACM
timeFrame: At 5 years
measure: Occurrence of major cardiac events in ACM
timeFrame: At 10 years
measure: Occurrence of major cardiac events in ACM
timeFrame: At 15 years
measure: Occurrence of major cardiac events in ACM
timeFrame: At 20 years
measure: Occurrence of major cardiac events in ACM
timeFrame: At 25 years
measure: Occurrence of major cardiac events in ACM
timeFrame: At 30 years
measure: Occurrence of major cardiac events in LVNC
timeFrame: At 1 year
measure: Occurrence of major cardiac events in LVNC
timeFrame: At 5 years
measure: Occurrence of major cardiac events in LVNC
timeFrame: At 10 years
measure: Occurrence of major cardiac events in LVNC
timeFrame: At 30 years
measure: Occurrence of major cardiac events in AMVP
timeFrame: At 1 year
measure: Occurrence of major cardiac events in AMVP
timeFrame: At 5 years
measure: Occurrence of major cardiac events in AMVP
timeFrame: At 10 years
measure: Occurrence of major cardiac events in AMVP
timeFrame: At 30 years
measure: Occurrence of major cardiac events in PPCM
timeFrame: At 1 year
measure: Occurrence of major cardiac events in PPCM
timeFrame: At 5 years
measure: Occurrence of major cardiac events in PPCM
timeFrame: At 10 years
measure: Occurrence of major cardiac events in PPCM
timeFrame: At 30 years
measure: Occurrence of major cardiac events in AFD
timeFrame: At 1 year
measure: Occurrence of major cardiac events in AFD
timeFrame: At 5 years
measure: Occurrence of major cardiac events in AFD
timeFrame: At 10 years
measure: Occurrence of major cardiac events in AFD
timeFrame: At 30 years
measure: Occurrence of major cardiac events in storage and dysmetabolic diseases
timeFrame: At 1 year
measure: Occurrence of major cardiac events in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Occurrence of major cardiac events in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Occurrence of major cardiac events in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Occurrence of major cardiac events in mitochondrial diseases
timeFrame: At 1 year
measure: Occurrence of major cardiac events in mitochondrial diseases
timeFrame: At 5 years
measure: Occurrence of major cardiac events in mitochondrial diseases
timeFrame: At 10 years
measure: Occurrence of major cardiac events in mitochondrial diseases
timeFrame: At 30 years
measure: Occurrence of major cardiac events in channelopathies with structural changeschannelopathies with structural changes
timeFrame: At 1 year
measure: Occurrence of major cardiac events in channelopathies with structural changes
timeFrame: At 5 years
measure: Occurrence of major cardiac events in channelopathies with structural changes
timeFrame: At 10 years
measure: Occurrence of major cardiac events in channelopathies with structural changes
timeFrame: At 30 years
measure: Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 1 year
measure: Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Occurrence of major cardiac events in overlapping phenotypes
timeFrame: At 1 year
measure: Occurrence of major cardiac events in overlapping phenotypes
timeFrame: At 5 years
measure: Occurrence of major cardiac events in overlapping phenotypes
timeFrame: At 10 years
measure: Occurrence of major cardiac events in overlapping phenotypes
timeFrame: At 30 years
measure: Occurrence of major cardiac events in undefined phenotypes
timeFrame: At 1 year
measure: Occurrence of major cardiac events in undefined phenotypes
timeFrame: At 5 years
measure: Occurrence of major cardiac events in undefined phenotypes
timeFrame: At 10 years
measure: Occurrence of major cardiac events in undefined phenotypes
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
timeFrame: At 30years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
timeFrame: At 30 years
Secondary outcomes:
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes
timeFrame: At 30 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
timeFrame: At baseline
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
timeFrame: At 5 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
timeFrame: At 10 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
timeFrame: At 15 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
timeFrame: At 20 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
timeFrame: At 25 years
measure: Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes
timeFrame: At 30 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
timeFrame: At baseline
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
timeFrame: At 5 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
timeFrame: At 10 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
timeFrame: At 15 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
timeFrame: At 20 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
timeFrame: At 25 years
measure: Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases
timeFrame: At 30 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
timeFrame: At baseline
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
timeFrame: At 5 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
timeFrame: At 10 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
timeFrame: At 15 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
timeFrame: At 20 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
timeFrame: At 25 years
measure: Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in NICMs
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in NICMs
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in NICMs
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in NICMs
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in NICMs
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in NICMs
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in NICMs
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in DCM
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in DCM
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in DCM
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in DCM
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in DCM
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in DCM
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in DCM
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in HCM
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in HCM
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in HCM
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in HCM
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in HCM
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in HCM
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in HCM
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in RCM
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in RCM
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in RCM
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in RCM
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in RCM
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in RCM
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in RCM
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in ACM
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in ACM
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in ACM
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in ACM
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in ACM
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in ACM
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in ACM
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in LVNC
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in LVNC
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in LVNC
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in LVNC
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in LVNC
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in LVNC
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in LVNC
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AMVP
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in AMVP
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AMVP
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AMVP
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AMVP
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AMVP
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AMVP
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in PPCM
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in PPCM
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in PPCM
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in PPCM
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in PPCM
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in PPCM
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in PPCM
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AFD
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in AFD
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AFD
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AFD
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AFD
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AFD
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in AFD
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
timeFrame: At baseline
measure: Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
timeFrame: At 5 years
measure: Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
timeFrame: At 10 years
measure: Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
timeFrame: At 15 years
measure: Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
timeFrame: At 20 years
measure: Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
timeFrame: At 25 years
measure: Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes
timeFrame: At 30 years
measure: Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
timeFrame: At baseline
measure: Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
timeFrame: At 5 years
measure: Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
timeFrame: At 10 years
measure: Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
timeFrame: At 15 years
measure: Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
timeFrame: At 20 years
measure: Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
timeFrame: At 25 years
measure: Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible
timeFrame: At 30 years
measure: Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
timeFrame: At baseline
measure: Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
timeFrame: At 5 years
measure: Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
timeFrame: At 10 years
measure: Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
timeFrame: At 15 years
measure: Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
timeFrame: At 20 years
measure: Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
timeFrame: At 25 years
measure: Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs
timeFrame: At 30 years
measure: Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
timeFrame: At baseline
measure: Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
timeFrame: At 5 years
measure: Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
timeFrame: At 10 years
measure: Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
timeFrame: At 15 years
measure: Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
timeFrame: At 20 years
measure: Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
timeFrame: At 25 years
measure: Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs
timeFrame: At 30 years
measure: Evaluation of healing timing of M-Infl in NICMs
timeFrame: At baseline
measure: Evaluation of healing timing of M-Infl in NICMs
timeFrame: At 5 years
measure: Evaluation of healing timing of M-Infl in NICMs
timeFrame: At 10 years
measure: Evaluation of healing timing of M-Infl in NICMs
timeFrame: At 15 years
measure: Evaluation of healing timing of M-Infl in NICMs
timeFrame: At 20 years
measure: Evaluation of healing timing of M-Infl in NICMs
timeFrame: At 25 years
measure: Evaluation of healing timing of M-Infl in NICMs
timeFrame: At 30 years
measure: Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
timeFrame: At baseline
measure: Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
timeFrame: At 5 years
measure: Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
timeFrame: At 10 years
measure: Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
timeFrame: At 15 years
measure: Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
timeFrame: At 20 years
measure: Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
timeFrame: At 25 years
measure: Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs
timeFrame: At 30 years
measure: Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
timeFrame: At baseline
measure: Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
timeFrame: At 5 years
measure: Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
timeFrame: At 10 years
measure: Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
timeFrame: At 15 years
measure: Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
timeFrame: At 20 years
measure: Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
timeFrame: At 25 years
measure: Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU
timeFrame: At 30 years
measure: Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
timeFrame: At baseline
measure: Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
timeFrame: At 5 years
measure: Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
timeFrame: At 10 years
measure: Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
timeFrame: At 15 years
measure: Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
timeFrame: At 20 years
measure: Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
timeFrame: At 25 years
measure: Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs
timeFrame: At 30 years
measure: Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
timeFrame: At baseline
measure: Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
timeFrame: At 5 years
measure: Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
timeFrame: At 10 years
measure: Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
timeFrame: At 15 years
measure: Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
timeFrame: At 20 years
measure: Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
timeFrame: At 25 years
measure: Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs
timeFrame: At 30 years
measure: Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
timeFrame: At baseline
measure: Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
timeFrame: At 5 years
measure: Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
timeFrame: At 10 years
measure: Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
timeFrame: At 15 years
measure: Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
timeFrame: At 20 years
measure: Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
timeFrame: At 25 years
measure: Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs
timeFrame: At 30 years
measure: Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
timeFrame: At baseline
measure: Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
timeFrame: At 5 years
measure: Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
timeFrame: At 10 years
measure: Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
timeFrame: At 15 years
measure: Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
timeFrame: At 20 years
measure: Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
timeFrame: At 25 years
measure: Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns
timeFrame: At 30 years
measure: Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
timeFrame: At baseline
measure: Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
timeFrame: At 5 years
measure: Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
timeFrame: At 10 years
measure: Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
timeFrame: At 15 years
measure: Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
timeFrame: At 20 years
measure: Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
timeFrame: At 25 years
measure: Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)
timeFrame: At 30 years
measure: Evaluation of coronary microvascular disease in NICMs
timeFrame: At baseline
measure: Evaluation of coronary microvascular disease in NICMs
timeFrame: At 5 years
measure: Evaluation of coronary microvascular disease in NICMs
timeFrame: At 10 years
measure: Evaluation of coronary microvascular disease in NICMs
timeFrame: At 15 years
measure: Evaluation of coronary microvascular disease in NICMs
timeFrame: At 20 years
measure: Evaluation of coronary microvascular disease in NICMs
timeFrame: At 25 years
measure: Evaluation of coronary microvascular disease in NICMs
timeFrame: At 30 years
measure: Assessment of myocardial ischemia in NICMs
timeFrame: At baseline
measure: Assessment of myocardial ischemia in NICMs
timeFrame: At 5 years
measure: Assessment of myocardial ischemia in NICMs
timeFrame: At 10 years
measure: Assessment of myocardial ischemia in NICMs
timeFrame: At 15 years
measure: Assessment of myocardial ischemia in NICMs
timeFrame: At 20 years
measure: Assessment of myocardial ischemia in NICMs
timeFrame: At 25 years
measure: Assessment of myocardial ischemia in NICMs
timeFrame: At 30 years
measure: Assessment of autoimmunity in NICMs
timeFrame: At baseline
measure: Assessment of autoimmunity in NICMs
timeFrame: At 5 years
measure: Assessment of autoimmunity in NICMs
timeFrame: At 10 years
measure: Assessment of autoimmunity in NICMs
timeFrame: At 15 years
measure: Assessment of autoimmunity in NICMs
timeFrame: At 20 years
measure: Assessment of autoimmunity in NICMs
timeFrame: At 25 years
measure: Assessment of autoimmunity in NICMs
timeFrame: At 30 years
measure: Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
timeFrame: At baseline
measure: Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
timeFrame: At 5 years
measure: Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
timeFrame: At 10 years
measure: Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
timeFrame: At 15 years
measure: Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
timeFrame: At 20 years
measure: Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
timeFrame: At 25 years
measure: Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs
timeFrame: At 30 years
measure: Assessment of hemodynamic changes in NICMs
timeFrame: At baseline
measure: Assessment of hemodynamic changes in NICMs
timeFrame: At 5 years
measure: Assessment of hemodynamic changes in NICMs
timeFrame: At 10 years
measure: Assessment of hemodynamic changes in NICMs
timeFrame: At 15 years
measure: Assessment of hemodynamic changes in NICMs
timeFrame: At 20 years
measure: Assessment of hemodynamic changes in NICMs
timeFrame: At 25 years
measure: Assessment of hemodynamic changes in NICMs
timeFrame: At 30 years
measure: Multimodal multiparametric imaging investigation of NICMs
timeFrame: At baseline
measure: Multimodal multiparametric imaging investigation of NICMs
timeFrame: At 5 years
measure: Multimodal multiparametric imaging investigation of NICMs
timeFrame: At 10 years
measure: Multimodal multiparametric imaging investigation of NICMs
timeFrame: At 15 years
measure: Multimodal multiparametric imaging investigation of NICMs
timeFrame: At 20 years
measure: Multimodal multiparametric imaging investigation of NICMs
timeFrame: At 25 years
measure: Multimodal multiparametric imaging investigation of NICMs
timeFrame: At 30 years
measure: Evaluation of differential diagnosis between NICMs and other cardiac diseases
timeFrame: At baseline
measure: Evaluation of differential diagnosis between NICMs and other cardiac diseases
timeFrame: At 5 years
measure: Evaluation of differential diagnosis between NICMs and other cardiac diseases
timeFrame: At 10 years
measure: Evaluation of differential diagnosis between NICMs and other cardiac diseases
timeFrame: At 15 years
measure: Evaluation of differential diagnosis between NICMs and other cardiac diseases
timeFrame: At 20 years
measure: Evaluation of differential diagnosis between NICMs and other cardiac diseases
timeFrame: At 25 years
measure: Evaluation of differential diagnosis between NICMs and other cardiac diseases
timeFrame: At 30 years
measure: Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
timeFrame: At baseline
measure: Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
timeFrame: At 5 years
measure: Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
timeFrame: At 10 years
measure: Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
timeFrame: At 15 years
measure: Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
timeFrame: At 20 years
measure: Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
timeFrame: At 25 years
measure: Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs
timeFrame: At 30 years
measure: Analysis of correlation between local and systemic/peripheral inflammation in NICMs
timeFrame: At baseline
measure: Analysis of correlation between local and systemic/peripheral inflammation in NICMs
timeFrame: At 5 years
measure: Analysis of correlation between local and systemic/peripheral inflammation in NICMs
timeFrame: At 10 years
measure: Analysis of correlation between local and systemic/peripheral inflammation in NICMs
timeFrame: At 15 years
measure: Analysis of correlation between local and systemic/peripheral inflammation in NICMs
timeFrame: At 20 years
measure: Analysis of correlation between local and systemic/peripheral inflammation in NICMs
timeFrame: At 25 years
measure: Analysis of correlation between local and systemic/peripheral inflammation in NICMs
timeFrame: At 30 years
measure: Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
timeFrame: At baseline
measure: Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
timeFrame: At 5 years
measure: Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
timeFrame: At 10 years
measure: Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
timeFrame: At 15 years
measure: Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
timeFrame: At 20 years
measure: Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
timeFrame: At 25 years
measure: Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)
timeFrame: At 30 years
measure: Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
timeFrame: At baseline
measure: Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
timeFrame: At 5 years
measure: Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
timeFrame: At 10 years
measure: Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
timeFrame: At 15 years
measure: Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
timeFrame: At 20 years
measure: Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
timeFrame: At 25 years
measure: Investigation of infectious, toxicologic, and immunologic factors associated with NICMs
timeFrame: At 30 years
measure: Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
timeFrame: At baseline
measure: Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
timeFrame: At 5 years
measure: Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
timeFrame: At 10 years
measure: Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
timeFrame: At 15 years
measure: Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
timeFrame: At 20 years
measure: Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
timeFrame: At 25 years
measure: Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment
timeFrame: At 30 years
measure: Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
timeFrame: At baseline
measure: Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
timeFrame: At 5 years
measure: Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
timeFrame: At 10 years
measure: Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
timeFrame: At 15 years
measure: Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
timeFrame: At 20 years
measure: Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
timeFrame: At 25 years
measure: Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs
timeFrame: At 30 years
measure: Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
timeFrame: At baseline
measure: Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
timeFrame: At 5 years
measure: Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
timeFrame: At 10 years
measure: Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
timeFrame: At 15 years
measure: Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
timeFrame: At 20 years
measure: Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
timeFrame: At 25 years
measure: Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs
timeFrame: At 30 years
measure: Diagnostic value of extracardiac diagnostic techniques in NICMs
timeFrame: At baseline
measure: Diagnostic value of extracardiac diagnostic techniques in NICMs
timeFrame: At 5 years
measure: Diagnostic value of extracardiac diagnostic techniques in NICMs
timeFrame: At 10 years
measure: Diagnostic value of extracardiac diagnostic techniques in NICMs
timeFrame: At 15 years
measure: Diagnostic value of extracardiac diagnostic techniques in NICMs
timeFrame: At 20 years
measure: Diagnostic value of extracardiac diagnostic techniques in NICMs
timeFrame: At 25 years
measure: Diagnostic value of extracardiac diagnostic techniques in NICMs
timeFrame: At 30 years
measure: Occurrence of minor events in DCM
timeFrame: At 1 year
measure: Occurrence of minor events in DCM
timeFrame: At 3 years
measure: Occurrence of minor events in DCM
timeFrame: At 5 years
measure: Occurrence of minor events in DCM
timeFrame: At 10 years
measure: Occurrence of minor events in DCM
timeFrame: At 15 years
measure: Occurrence of minor events in DCM
timeFrame: At 20 years
measure: Occurrence of minor events in DCM
timeFrame: At 25 years
measure: Occurrence of minor events in DCM
timeFrame: At 30 years
measure: Occurrence of minor events in HCM
timeFrame: At 1 year
measure: Occurrence of minor events in HCM
timeFrame: At 3 years
measure: Occurrence of minor events in HCM
timeFrame: At 5 years
measure: Occurrence of minor events in HCM
timeFrame: At 10 years
measure: Occurrence of minor events in HCM
timeFrame: At 15 years
measure: Occurrence of minor events in HCM
timeFrame: At 20 years
measure: Occurrence of minor events in HCM
timeFrame: At 25 years
measure: Occurrence of minor events in HCM
timeFrame: At 30 years
measure: Occurrence of minor events in RCM
timeFrame: At 1 year
measure: Occurrence of minor events in RCM
timeFrame: At 3 years
measure: Occurrence of minor events in RCM
timeFrame: At 5 years
measure: Occurrence of minor events in RCM
timeFrame: At 10 years
measure: Occurrence of minor events in RCM
timeFrame: At 15 years
measure: Occurrence of minor events in RCM
timeFrame: At 20 years
measure: Occurrence in minor events in RCM
timeFrame: At 25 years
measure: Occurrence of minor events in RCM
timeFrame: At 30 years
measure: Occurrence of minor events in ACM
timeFrame: At 1 year
measure: Occurrence of minor events in ACM
timeFrame: At 3 years
measure: Occurrence of minor events in ACM
timeFrame: At 5 years
measure: Occurrence of minor events in ACM
timeFrame: At 10 years
measure: Occurrence of minor events in ACM
timeFrame: At 15 years
measure: Occurrence of minor events in ACM
timeFrame: At 20 years
measure: Occurrence of minor events in ACM
timeFrame: At 25 years
measure: Occurrence of minor events in ACM
timeFrame: At 30 years
measure: Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases
timeFrame: At 1 year
measure: Occurrence of minor events in distinct cardiomyopathic phenotypes have been described in some diseases
timeFrame: At 5 years
measure: Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases
timeFrame: At 10 years
measure: Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases
timeFrame: At 30 years
measure: Occurrence of minor events in overlapping and undefined phenotypes
timeFrame: At 1 year
measure: Occurrence of minor events in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Occurrence of minor events in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Occurrence of minor events in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 1 year
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 3 years
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 5 years
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 10 years
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 15 years
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 20 years
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 25 years
measure: Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.
timeFrame: At 30 years
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 1 year
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 3 years
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 5 years
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 10 years
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 15 years
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 20 years
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 25 years
measure: Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs
timeFrame: At 30 years
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 1 year
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 3 years
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 5 years
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 10 years
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 15 years
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 20 years
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 25 years
measure: Identification of biomarkers associated with treatment response for NICMs
timeFrame: At 30 years
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 1 year
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 3 years
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 5 years
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 10 years
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 15 years
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 20 years
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 25 years
measure: Identification of cost-effective multimodal and multiparametric risk scores for NICMs
timeFrame: At 30 years
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 1 year
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 3 years
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 5 years
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 10 years
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 15 years
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 20 years
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 25 years
measure: Assessment of the prognostic value of arrhythmias in NICMs
timeFrame: At 30 years
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 1 year
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 3 years
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 5 years
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 10 years
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 15 years
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 20 years
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 25 years
measure: Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs
timeFrame: At 30 years
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 1 year
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 3 years
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 5 years
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 10 years
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 15 years
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 20 years
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 25 years
measure: Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events
timeFrame: At 30 years
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 1 year
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 3 years
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 5 years
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 10 years
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 15 years
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 20 years
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 25 years
measure: Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events
timeFrame: At 30 years
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 1 year
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 3 years
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 5 years
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 10 years
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 15 years
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 20 years
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 25 years
measure: Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events
timeFrame: At 30 years
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 1 year
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 3 years
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 5 years
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 10 years
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 15 years
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 20 years
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 25 years
measure: Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events
timeFrame: At 30 years
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 1 year
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 3 years
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 5 years
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 10 years
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 15 years
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 20 years
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 25 years
measure: Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in DCM
timeFrame: At baseline
measure: Assessment of epidemiology signatures in DCM
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in DCM
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in DCM
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in DCM
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in DCM
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in DCM
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in HCM
timeFrame: At baseline
measure: Assessment of epidemiology signatures in HCM
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in HCM
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in HCM
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in HCM
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in HCM
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in HCM
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in RCM
timeFrame: At baseline
measure: Assessment of epidemiology signatures in RCM
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in RCM
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in RCM
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in RCM
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in RCM
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in RCM
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in ACM
timeFrame: At baseline
measure: Assessment of epidemiology signatures in ACM
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in ACM
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in ACM
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in ACM
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in ACM
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in ACM
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in LVNC
timeFrame: At baseline
measure: Assessment of epidemiology signatures in LVNC
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in LVNC
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in LVNC
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in LVNC
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in LVNC
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in LVNC
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in AMVP
timeFrame: At baseline
measure: Assessment of epidemiology signatures in AMVP
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in AMVP
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in AMVP
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in AMVP
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in AMVP
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in AMVP
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in PPCM
timeFrame: At baseline
measure: Assessment of epidemiology signatures in PPCM
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in PPCM
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in PPCM
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in PPCM
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in PPCM
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in PPCM
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in AFD
timeFrame: At baseline
measure: Assessment of epidemiology signatures in AFD
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in AFD
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in AFD
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in AFD
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in AFD
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in AFD
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of epidemiology signatures in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of epidemiology signatures in mitochondrial diseases
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in mitochondrial diseases
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in mitochondrial diseases
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in mitochondrial diseases
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in mitochondrial diseases
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in mitochondrial diseases
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of epidemiology signatures in channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of epidemiology signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of epidemiology signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of epidemiology signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of epidemiology signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of epidemiology signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of epidemiology signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of epidemiology signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of etiology signatures in DCM
timeFrame: At baseline
measure: Assessment of etiology signatures in DCM
timeFrame: At 5 years
measure: Assessment of etiology signatures in DCM
timeFrame: At 10 years
measure: Assessment of etiology signatures in DCM
timeFrame: At 15 years
measure: Assessment of etiology signatures in DCM
timeFrame: At 20 years
measure: Assessment of etiology signatures in DCM
timeFrame: At 25 years
measure: Assessment of etiology signatures in DCM
timeFrame: At 30 years
measure: Assessment of etiology signatures in HCM
timeFrame: At baseline
measure: Assessment of etiology signatures in HCM
timeFrame: At 5 years
measure: Assessment of etiology signatures in HCM
timeFrame: At 10 years
measure: Assessment of etiology signatures in HCM
timeFrame: At 15 years
measure: Assessment of etiology signatures in HCM
timeFrame: At 20 years
measure: Assessment of etiology signatures in HCM
timeFrame: At 25 years
measure: Assessment of etiology signatures in HCM
timeFrame: At 30 years
measure: Assessment of etiology signatures in RCM
timeFrame: At baseline
measure: Assessment of etiology signatures in RCM
timeFrame: At 5 years
measure: Assessment of etiology signatures in RCM
timeFrame: At 10 years
measure: Assessment of etiology signatures in RCM
timeFrame: At 15 years
measure: Assessment of etiology signatures in RCM
timeFrame: At 20 years
measure: Assessment of etiology signatures in RCM
timeFrame: At 25 years
measure: Assessment of etiology signatures in RCM
timeFrame: At 30 years
measure: Assessment of etiology signatures in ACM
timeFrame: At baseline
measure: Assessment of etiology signatures in ACM
timeFrame: At 5 years
measure: Assessment of etiology signatures in ACM
timeFrame: At 10 years
measure: Assessment of etiology signatures in ACM
timeFrame: At 15 years
measure: Assessment of etiology signatures in ACM
timeFrame: At 20 years
measure: Assessment of etiology signatures in ACM
timeFrame: At 25 years
measure: Assessment of etiology signatures in ACM
timeFrame: At 30 years
measure: Assessment of etiology signatures in LVNC
timeFrame: At baseline
measure: Assessment of etiology signatures in LVNC
timeFrame: At 5 years
measure: Assessment of etiology signatures in LVNC
timeFrame: At 10 years
measure: Assessment of etiology signatures in LVNC
timeFrame: At 15 years
measure: Assessment of etiology signatures in LVNC
timeFrame: At 20 years
measure: Assessment of etiology signatures in LVNC
timeFrame: At 25 years
measure: Assessment of etiology signatures in LVNC
timeFrame: At 30 years
measure: Assessment of etiology signatures in AMVP
timeFrame: At baseline
measure: Assessment of etiology signatures in AMVP
timeFrame: At 5 years
measure: Assessment of etiology signatures in AMVP
timeFrame: At 10 years
measure: Assessment of etiology signatures in AMVP
timeFrame: At 15 years
measure: Assessment of etiology signatures in AMVP
timeFrame: At 20 years
measure: Assessment of etiology signatures in AMVP
timeFrame: At 25 years
measure: Assessment of etiology signatures in AMVP
timeFrame: At 30 years
measure: Assessment of etiology signatures in PPCM
timeFrame: At baseline
measure: Assessment of etiology signatures in PPCM
timeFrame: At 5 years
measure: Assessment of etiology signatures in PPCM
timeFrame: At 10 years
measure: Assessment of etiology signatures in PPCM
timeFrame: At 15 years
measure: Assessment of etiology signatures in PPCM
timeFrame: At 20 years
measure: Assessment of etiology signatures in PPCM
timeFrame: At 25 years
measure: Assessment of etiology signatures in PPCM
timeFrame: At 30 years
measure: Assessment of etiology signatures in AFD
timeFrame: At baseline
measure: Assessment of etiology signatures in AFD
timeFrame: At 5 years
measure: Assessment of etiology signatures in AFD
timeFrame: At 10 years
measure: Assessment of etiology signatures in AFD
timeFrame: At 15 years
measure: Assessment of etiology signatures in AFD
timeFrame: At 20 years
measure: Assessment of etiology signatures in AFD
timeFrame: At 25 years
measure: Assessment of etiology signatures in AFD
timeFrame: At 30 years
measure: Assessment of etiology signatures in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of etiology signatures in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Assessment of etiology signatures in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Assessment of etiology signatures in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Assessment of etiology signatures in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Assessment of etiology signatures in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Assessment of etiology signatures in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Assessment of etiology signatures in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of etiology signatures in mitochondrial diseases
timeFrame: At 5 years
measure: Assessment of etiology signatures in mitochondrial diseases
timeFrame: At 10 years
measure: Assessment of etiology signatures in mitochondrial diseases
timeFrame: At 15 years
measure: Assessment of etiology signatures in mitochondrial diseases
timeFrame: At 20 years
measure: Assessment of etiology signatures in mitochondrial diseases
timeFrame: At 25 years
measure: Assessment of etiology signatures in mitochondrial diseases
timeFrame: At 30 years
measure: Assessment of etiology signatures in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of etiology signatures in channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of etiology signatures in channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of etiology signatures in channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of etiology signatures in channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of etiology signatures in channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of etiology signatures in channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of etiology signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of etiology signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of etiology signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of etiology signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of etiology signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of etiology signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in DCM
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in DCM
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in DCM
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in DCM
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in DCM
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in DCM
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in DCM
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in HCM
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in HCM
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in HCM
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in HCM
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in HCM
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in HCM
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in HCM
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in RCM
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in RCM
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in RCM
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in RCM
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in RCM
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in RCM
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in RCM
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in ACM
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in ACM
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in ACM
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in ACM
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in ACM
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in ACM
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in ACM
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in LVNC
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in LVNC
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in LVNC
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in LVNC
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in LVNC
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in LVNC
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in LVNC
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in AMVP
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in AMVP
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in AMVP
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in AMVP
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in AMVP
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in AMVP
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in AMVP
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in PPCM
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in PPCM
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in PPCM
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in PPCM
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in PPCM
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in PPCM
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in PPCM
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in AFD
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in AFD
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in AFD
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in AFD
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in AFD
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in AFD
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in AFD
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in mitochondrial diseases
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in mitochondrial diseases
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in mitochondrial diseases
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in mitochondrial diseases
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in mitochondrial diseases
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in mitochondrial diseases
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of pathophysiology signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of pathophysiology signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of pathophysiology signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of pathophysiology signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of pathophysiology signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of pathophysiology signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of pathophysiology signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in DCM
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in DCM
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in DCM
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in DCM
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in DCM
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in DCM
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in DCM
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in HCM
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in HCM
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in HCM
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in HCM
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in HCM
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in HCM
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in HCM
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in RCM
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in RCM
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in RCM
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in RCM
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in RCM
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in RCM
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in RCM
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in ACM
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in ACM
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in ACM
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in ACM
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in ACM
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in ACM
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in ACM
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in LVNC
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in LVNC
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in LVNC
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in LVNC
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in LVNC
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in LVNC
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in LVNC
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in AMVP
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in AMVP
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in AMVP
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in AMVP
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in AMVP
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in AMVP
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in AMVP
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in PPCM
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in PPCM
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in PPCM
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in PPCM
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in PPCM
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in PPCM
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in PPCM
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in AFD
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in AFD
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in AFD
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in AFD
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in AFD
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in AFD
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in AFD
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in mitochondrial diseases
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in mitochondrial diseases
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in mitochondrial diseases
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in mitochondrial diseases
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in mitochondrial diseases
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in mitochondrial diseases
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in DCM
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in DCM
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in DCM
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in DCM
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in DCM
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in DCM
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in DCM
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in HCM
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in HCM
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in RCM
timeFrame: Every 10 years
measure: Assessment of arrhythmia signatures in ACM
timeFrame: Every 15 years
measure: Assessment of arrhythmia signatures in ACM
timeFrame: Every 20 years
measure: Assessment of arrhythmia signatures in ACM
timeFrame: Every 25 years
measure: Assessment of arrhythmia signatures in ACM
timeFrame: Every 30 years
measure: Assessment of arrhythmia signatures in LVNC
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in LVNC
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in LVNC
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in LVNC
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in LVNC
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in LVNC
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in LVNC
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in AMVP
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in AMVP
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in AMVP
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in AMVP
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in AMVP
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in AMVP
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in AMVP
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in PPCM
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in PPCM
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in PPCM
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in PPCM
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in PPCM
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in PPCM
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in PPCM
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in AFD
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in AFD
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in AFD
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in AFD
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in AFD
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in AFD
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in AFD
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in mitochondrial diseases
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in mitochondrial diseases
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in mitochondrial diseases
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in mitochondrial diseases
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in mitochondrial diseases
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in mitochondrial diseases
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of arrhythmia signatures in overlapping and undefined phenotype
timeFrame: At baseline
measure: Assessment of arrhythmia signatures in overlapping and undefined phenotype
timeFrame: At 5 years
measure: Assessment of arrhythmia signatures in overlapping and undefined phenotype
timeFrame: At 10 years
measure: Assessment of arrhythmia signatures in overlapping and undefined phenotype
timeFrame: At 15 years
measure: Assessment of arrhythmia signatures in overlapping and undefined phenotype
timeFrame: At 20 years
measure: Assessment of arrhythmia signatures in overlapping and undefined phenotype
timeFrame: At 25 years
measure: Assessment of arrhythmia signatures in overlapping and undefined phenotype
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in DCM
timeFrame: At baseline
measure: Assessment of M-Infl signatures in DCM
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in DCM
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in DCM
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in DCM
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in DCM
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in DCM
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in HCM
timeFrame: At baseline
measure: Assessment of M-Infl signatures in HCM
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in HCM
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in HCM
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in HCM
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in HCM
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in HCM
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in RCM
timeFrame: At baseline
measure: Assessment of M-Infl signatures in RCM
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in RCM
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in RCM
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in RCM
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in RCM
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in RCM
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in ACM
timeFrame: At baseline
measure: Assessment of M-Infl signatures in ACM
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in ACM
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in ACM
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in ACM
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in ACM
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in ACM
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in LVNC
timeFrame: At baseline
measure: Assessment of M-Infl signatures in LVNC
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in LVNC
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in LVNC
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in LVNC
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in LVNC
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in LVNC
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in AMVP
timeFrame: At baseline
measure: Assessment of M-Infl signatures in AMVP
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in AMVP
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in AMVP
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in AMVP
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in AMVP
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in AMVP
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in PPCM
timeFrame: At baseline
measure: Assessment of M-Infl signatures in PPCM
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in PPCM
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in PPCM
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in PPCM
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in PPCM
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in PPCM
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in AFD
timeFrame: At baseline
measure: Assessment of M-Infl signatures in AFD
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in AFD
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in AFD
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in AFD
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in AFD
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in AFD
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of M-Infl signatures in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of M-Infl signatures in mitochondrial diseases
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in mitochondrial diseases
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in mitochondrial diseases
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in mitochondrial diseases
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in mitochondrial diseases
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in mitochondrial diseases
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of M-Infl signatures in channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of M-Infl signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of M-Infl signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of M-Infl signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of M-Infl signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of M-Infl signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of M-Infl signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of M-Infl signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in DCM
timeFrame: At baseline
measure: Assessment of extracardiac signatures in DCM
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in DCM
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in DCM
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in DCM
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in DCM
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in DCM
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in HCM
timeFrame: At baseline
measure: Assessment of extracardiac signatures in HCM
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in HCM
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in HCM
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in HCM
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in HCM
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in HCM
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in RCM
timeFrame: At baseline
measure: Assessment of extracardiac signatures in RCM
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in RCM
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in RCM
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in RCM
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in RCM
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in RCM
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in ACM
timeFrame: At baseline
measure: Assessment of extracardiac signatures in ACM
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in ACM
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in ACM
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in ACM
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in ACM
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in ACM
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in LVNC
timeFrame: At baseline
measure: Assessment of extracardiac signatures in LVNC
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in LVNC
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in LVNC
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in LVNC
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in LVNC
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in LVNC
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in AMVP
timeFrame: At baseline
measure: Assessment of extracardiac signatures in AMVP
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in AMVP
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in AMVP
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in AMVP
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in AMVP
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in AMVP
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in PPCM
timeFrame: At baseline
measure: Assessment of extracardiac signatures in PPCM
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in PPCM
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in PPCM
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in PPCM
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in PPCM
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in PPCM
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in AFD
timeFrame: At baseline
measure: Assessment of extracardiac signatures in AFD
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in AFD
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in AFD
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in AFD
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in AFD
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in AFD
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in storage and dysmetabolic diseases
timeFrame: At baseline
measure: Assessment of extracardiac signatures in storage and dysmetabolic diseases
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in storage and dysmetabolic diseases
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in storage and dysmetabolic diseases
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in storage and dysmetabolic diseases
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in storage and dysmetabolic diseases
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in storage and dysmetabolic diseases
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in mitochondrial diseases
timeFrame: At baseline
measure: Assessment of extracardiac signatures in mitochondrial diseases
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in mitochondrial diseases
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in mitochondrial diseases
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in mitochondrial diseases
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in mitochondrial diseases
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in mitochondrial diseases
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of extracardiac signatures in channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of extracardiac signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of extracardiac signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of extracardiac signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of extracardiac signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of extracardiac signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of extracardiac signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of extracardiac signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
timeFrame: At baseline
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
timeFrame: At 5 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
timeFrame: At 10 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
timeFrame: At 15 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
timeFrame: At 20 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
timeFrame: At 25 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM
timeFrame: At 30 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
timeFrame: At baseline
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
timeFrame: At 5 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
timeFrame: At 10 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
timeFrame: At 15 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
timeFrame: At 20 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
timeFrame: At 25 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM
timeFrame: At 30 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
timeFrame: At baseline
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
timeFrame: At 5 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
timeFrame: At 10 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
timeFrame: At 15 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
timeFrame: At 20 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
timeFrame: At 25 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM
timeFrame: At 30 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
timeFrame: At baseline
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
timeFrame: At 5 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
timeFrame: At 10 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
timeFrame: At 15 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
timeFrame: At 20 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
timeFrame: At 25 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM
timeFrame: At 30 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of prognostic signatures in DCM
timeFrame: At baseline
measure: Assessment of prognostic signatures in DCM
timeFrame: At 5 years
measure: Assessment of prognostic signatures in DCM
timeFrame: At 10 years
measure: Assessment of prognostic signatures in DCM
timeFrame: At 15 years
measure: Assessment of prognostic signatures in DCM
timeFrame: At 20 years
measure: Assessment of prognostic signatures in DCM
timeFrame: At 25 years
measure: Assessment of prognostic signatures in DCM
timeFrame: At 30 years
measure: Assessment of prognostic signatures in HCM
timeFrame: At baseline
measure: Assessment of prognostic signatures in HCM
timeFrame: At 5 years
measure: Assessment of prognostic signatures in HCM
timeFrame: At 10 years
measure: Assessment of prognostic signatures in HCM
timeFrame: At 15 years
measure: Assessment of prognostic signatures in HCM
timeFrame: At 20 years
measure: Assessment of prognostic signatures in HCM
timeFrame: At 25 years
measure: Assessment of prognostic signatures in HCM
timeFrame: At 30 years
measure: Assessment of prognostic signatures in RCM
timeFrame: At baseline
measure: Assessment of prognostic signatures in RCM
timeFrame: At 5 years
measure: Assessment of prognostic signatures in RCM
timeFrame: At 10 years
measure: Assessment of prognostic signatures in RCM
timeFrame: At 15 years
measure: Assessment of prognostic signatures in RCM
timeFrame: At 20 years
measure: Assessment of prognostic signatures in RCM
timeFrame: At 25 years
measure: Assessment of prognostic signatures in RCM
timeFrame: At 30 years
measure: Assessment of prognostic signatures in ACM
timeFrame: At baseline
measure: Assessment of prognostic signatures in ACM
timeFrame: At 5 years
measure: Assessment of prognostic signatures in ACM
timeFrame: At 10 years
measure: Assessment of prognostic signatures in ACM
timeFrame: At 15 years
measure: Assessment of prognostic signatures in ACM
timeFrame: At 20 years
measure: Assessment of prognostic signatures in ACM
timeFrame: At 25 years
measure: Assessment of prognostic signatures in ACM
timeFrame: At 30 years
measure: Assessment of prognostic signatures in LVNC
timeFrame: At baseline
measure: Assessment of prognostic signatures in LVNC
timeFrame: At 5 years
measure: Assessment of prognostic signatures in LVNC
timeFrame: At 10 years
measure: Assessment of prognostic signatures in LVNC
timeFrame: At 15 years
measure: Assessment of prognostic signatures in LVNC
timeFrame: At 20 years
measure: Assessment of prognostic signatures in LVNC
timeFrame: At 25 years
measure: Assessment of prognostic signatures in LVNC
timeFrame: At 30 years
measure: Assessment of prognostic signatures in AMVP
timeFrame: At baseline
measure: Assessment of prognostic signatures in AMVP
timeFrame: At 5 years
measure: Assessment of prognostic signatures in AMVP
timeFrame: At 10 years
measure: Assessment of prognostic signatures in AMVP
timeFrame: At 15 years
measure: Assessment of prognostic signatures in AMVP
timeFrame: At 20 years
measure: Assessment of prognostic signatures in AMVP
timeFrame: At 25 years
measure: Assessment of prognostic signatures in AMVP
timeFrame: At 30 years
measure: Assessment of prognostic signatures in PPCM
timeFrame: At baseline
measure: Assessment of prognostic signatures in PPCM
timeFrame: At 5 years
measure: Assessment of prognostic signatures in PPCM
timeFrame: At 10 years
measure: Assessment of prognostic signatures in PPCM
timeFrame: At 15 years
measure: Assessment of prognostic signatures in PPCM
timeFrame: At 20 years
measure: Assessment of prognostic signatures in PPCM
timeFrame: At 25 years
measure: Assessment of prognostic signatures in PPCM
timeFrame: At 30 years
measure: Assessment of prognostic signatures in AFD
timeFrame: At baseline
measure: Assessment of prognostic signatures in AFD
timeFrame: At 5 years
measure: Assessment of prognostic signatures in AFD
timeFrame: At 10 years
measure: Assessment of prognostic signatures in AFD
timeFrame: At 15 years
measure: Assessment of prognostic signatures in AFD
timeFrame: At 20 years
measure: Assessment of prognostic signatures in AFD
timeFrame: At 25 years
measure: Assessment of prognostic signatures in AFD
timeFrame: At 30 years
measure: Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of prognostic signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of prognostic signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of prognostic signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of prognostic signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of prognostic signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of prognostic signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of prognostic signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in DCM
timeFrame: At baseline
measure: Assessment of response to treatment signatures in DCM
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in DCM
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in DCM
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in DCM
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in DCM
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in DCM
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in HCM
timeFrame: At baseline
measure: Assessment of response to treatment signatures in HCM
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in HCM
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in HCM
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in HCM
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in HCM
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in HCM
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in RCM
timeFrame: At baseline
measure: Assessment of response to treatment signatures in RCM
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in RCM
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in RCM
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in RCM
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in RCM
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in RCM
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in ACM
timeFrame: At baseline
measure: Assessment of response to treatment signatures in ACM
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in ACM
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in ACM
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in ACM
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in ACM
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in ACM
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in LVNC
timeFrame: At baseline
measure: Assessment of response to treatment signatures in LVNC
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in LVNC
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in LVNC
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in LVNC
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in LVNC
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in LVNC
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in AMVP
timeFrame: At baseline
measure: Assessment of response to treatment signatures in AMVP
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in AMVP
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in AMVP
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in AMVP
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in AMVP
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in AMVP
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in PPCM
timeFrame: At baseline
measure: Assessment of response to treatment signatures in PPCM
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in PPCM
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in PPCM
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in PPCM
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in PPCM
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in PPCM
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in AFD
timeFrame: At baseline
measure: Assessment of response to treatment signatures in AFD
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in AFD
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in AFD
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in AFD
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in AFD
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in AFD
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Assessment of response to treatment signatures in overlapping and undefined phenotypes
timeFrame: At baseline
measure: Assessment of response to treatment signatures in overlapping and undefined phenotypes
timeFrame: At 5 years
measure: Assessment of response to treatment signatures in overlapping and undefined phenotypes
timeFrame: At 10 years
measure: Assessment of response to treatment signatures in overlapping and undefined phenotypes
timeFrame: At 15 years
measure: Assessment of response to treatment signatures in overlapping and undefined phenotypes
timeFrame: At 20 years
measure: Assessment of response to treatment signatures in overlapping and undefined phenotypes
timeFrame: At 25 years
measure: Assessment of response to treatment signatures in overlapping and undefined phenotypes
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: At 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At baseline
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 5 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 10 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 15 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 20 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 25 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: At 30 years
measure: Evaluation of efficacy of pharmacological antiarrhythmic treatment on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: By 30 years
measure: Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in overlapping and undefined phenotypes Efficacy of pharmacological antiarrhythmic treatment on major and minor events
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in DCM
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in HCM
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in RCM
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in ACM
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in LVNC
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AMVP
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in PPCM
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AFD
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in overlapping and undefined phenotypes
timeFrame: By 30 years
measure: Identification of criteria for device implants (PM, ICD, S-ICD, CRT-D...) in NICMs patients
timeFrame: By 30 years
measure: Identification of the most suitable therapeutic strategies based on indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes
timeFrame: By 30 years
measure: Identification of the best candidates to multidisciplinary management of NICMs
timeFrame: By 30 years
measure: Indication and timing for device (ICD, CRT-D) implant in primary prevention, based on multidisciplinary, multimodal, multiparametric risk assessment in NICMs, and in relation to different general and etiology-dependent treatments
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in DCM patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in HCM patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in RCM patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in ACM patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in LVNC patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in PPCM patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AMVP patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AFD patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in storage and dysmetabolic diseases patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in mitochondrial diseases patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in channelopathies with structural changes patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with overlapping and undefined phenotypes patients, i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in DCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in HCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in RCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in ACM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in LVNC patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AMVP patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in PPCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AFD patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in storage and dysmetabolic diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in mitochondrial diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in channelopathies with structural change patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, , i.e. effects on major and minor events
timeFrame: By 30 years
measure: Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in overlapping and undefined phenotypes patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in channelopathies with structural changes i.e. effects on major and minor events.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.
timeFrame: By 30 years
measure: Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in overlapping and undefined phenotypes i.e. effects on major and minor events.
timeFrame: By 30 years
measure: Efficacy of etiology -specific treatments, including those aimed to target extra - cardiac disease manifestations in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.
timeFrame: By 30 years
measure: Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of replacement therapy, molecular therapy, gene therapy in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.
timeFrame: By 30 years
measure: Efficacy of heart transplantation and other treatment for end-stage heart failure in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in DCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in HCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in RCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in ACM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in LVNC, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in AMVP, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in PPCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in AFD, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in storage and dysmetabolic diseases, mitochondrial diseases, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in channelopathies with structural changes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, i.e. effects on major and minor event i.e. effects on major and minor events.
timeFrame: By 30 years
measure: Efficacy of surgical or hemodynamic procedures in overlapping and undefined phenotypes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.
timeFrame: By 30 years
measure: Investigation of cardiac device implant in primary and secondary prevention, in all patients, as well as in subgroups with and without M-Infl in NICMs
timeFrame: By 30 years
measure: Investigation of ablation of cardiac arrhythmias (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes) in NICMs
timeFrame: By 30 years
measure: Role of ablation (any technique) on arrhythmic outcomes in NICMs, in all patients, as well as in subgroups with and without arrhythmias and MInfl
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in HCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in ACM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in LVNC, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in AMVP, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in PPCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in AFD, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in storage and dysmetabolic diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in mitochondrial diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in channelopathies with structural changes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures rheumatologic or neuromuscular diseases
timeFrame: By 30 years
measure: Indications and optimal timing for any electrophysiological or interventional procedures in overlapping and undefined phenotypes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings
timeFrame: By 30 years
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS San Raffaele Scientific Institute
state: Milano
Study officials:
affiliation: San Raffaele Scientific Institute, Milan, Italy
name: Paolo Della Bella, MD
role: STUDY_CHAIR
References:
citation: Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, De Gaspari M, Rigato I, Leoni L, Zorzi A, De Lazzari M, Rampazzo A, Iliceto S, Thiene G, Corrado D, Pilichou K, Basso C, Perazzolo Marra M, Bauce B. 'Hot phase' clinical presentation in arrhythmogenic cardiomyopathy. Europace. 2021 Jun 7;23(6):907-917. doi: 10.1093/europace/euaa343.
citation: Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996 Sep 1;94(5):983-91. doi: 10.1161/01.cir.94.5.983.
citation: Peretto G, De Luca G, Campochiaro C, Palmisano A, Busnardo E, Sartorelli S, Barzaghi F, Cicalese MP, Esposito A, Sala S. Telemedicine in myocarditis: Evolution of a mutidisciplinary "disease unit" at the time of COVID-19 pandemic. Am Heart J. 2020 Nov;229:121-126. doi: 10.1016/j.ahj.2020.07.015. Epub 2020 Aug 12.
citation: Peretto G, Sala S, Della Bella P. [Diagnostic and therapeutic approach to myocarditis patients presenting with arrhythmias]. G Ital Cardiol (Rome). 2020 Mar;21(3):187-194. doi: 10.1714/3306.32767. Italian.
citation: Della Bella P, Baratto F, Vergara P, Bertocchi P, Santamaria M, Notarstefano P, Calo L, Orsida D, Tomasi L, Piacenti M, Sangiorgio S, Pentimalli F, Pruvot E, De Sousa J, Sacher F, Tritto M, Rebellato L, Deneke T, Romano SA, Nesti M, Gargaro A, Giacopelli D, Peretto G, Radinovic A. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022 Jun 21;145(25):1829-1838. doi: 10.1161/CIRCULATIONAHA.122.059598. Epub 2022 Apr 3.
citation: Della Bella P, Baratto F, Tsiachris D, Trevisi N, Vergara P, Bisceglia C, Petracca F, Carbucicchio C, Benussi S, Maisano F, Alfieri O, Pappalardo F, Zangrillo A, Maccabelli G. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation. Circulation. 2013 Apr 2;127(13):1359-68. doi: 10.1161/CIRCULATIONAHA.112.000872. Epub 2013 Feb 25.
citation: De Luca G, Campochiaro C, Sartorelli S, Peretto G, Dagna L. Therapeutic strategies for virus-negative myocarditis: a comprehensive review. Eur J Intern Med. 2020 Jul;77:9-17. doi: 10.1016/j.ejim.2020.04.050. Epub 2020 May 10.
citation: Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, Stalens C, Sacher F, Babuty D, Trochu JN, Moubarak G, Savvatis K, Porcher R, Laforet P, Fayssoil A, Marijon E, Stojkovic T, Behin A, Leonard-Louis S, Sole G, Labombarda F, Richard P, Metay C, Quijano-Roy S, Dabaj I, Klug D, Vantyghem MC, Chevalier P, Ambrosi P, Salort E, Sadoul N, Waintraub X, Chikhaoui K, Mabo P, Combes N, Maury P, Sellal JM, Tedrow UB, Kalman JM, Vohra J, Androulakis AFA, Zeppenfeld K, Thompson T, Barnerias C, Becane HM, Bieth E, Boccara F, Bonnet D, Bouhour F, Boule S, Brehin AC, Chapon F, Cintas P, Cuisset JM, Davy JM, De Sandre-Giovannoli A, Demurger F, Desguerre I, Dieterich K, Durigneux J, Echaniz-Laguna A, Eschalier R, Ferreiro A, Ferrer X, Francannet C, Fradin M, Gaborit B, Gay A, Hagege A, Isapof A, Jeru I, Juntas Morales R, Lagrue E, Lamblin N, Lascols O, Laugel V, Lazarus A, Leturcq F, Levy N, Magot A, Manel V, Martins R, Mayer M, Mercier S, Meune C, Michaud M, Minot-Myhie MC, Muchir A, Nadaj-Pakleza A, Pereon Y, Petiot P, Petit F, Praline J, Rollin A, Sabouraud P, Sarret C, Schaeffer S, Taithe F, Tard C, Tiffreau V, Toutain A, Vatier C, Walther-Louvier U, Eymard B, Charron P, Vigouroux C, Bonne G, Kumar S, Elliott P, Duboc D. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation. 2019 Jul 23;140(4):293-302. doi: 10.1161/CIRCULATIONAHA.118.039410. Epub 2019 Jun 3.
citation: Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, Bourfiss M, Fortier A, Lie OH, Saguner AM, Svensson A, Andorin A, Tichnell C, Murray B, Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn AD, Talajic M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge DP, Yap SC, van der Heijden JF, Tandri H, Jongbloed JDH, Guertin MC, van Tintelen JP, Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins H, Te Riele ASJM, James CA. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019 Jun 14;40(23):1850-1858. doi: 10.1093/eurheartj/ehz103.
citation: O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.
citation: Augusto JB, Eiros R, Nakou E, Moura-Ferreira S, Treibel TA, Captur G, Akhtar MM, Protonotarios A, Gossios TD, Savvatis K, Syrris P, Mohiddin S, Moon JC, Elliott PM, Lopes LR. Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging. 2020 Mar 1;21(3):326-336. doi: 10.1093/ehjci/jez188.
citation: Zorzi A, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A, Pilichou K, Migliore F, Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L, Patrizi G, De Maria E, Pelliccia A, Basso C, Schiavon M, Bauce B, Iliceto S, Thiene G, Corrado D. Nonischemic Left Ventricular Scar as a Substrate of Life-Threatening Ventricular Arrhythmias and Sudden Cardiac Death in Competitive Athletes. Circ Arrhythm Electrophysiol. 2016 Jul;9(7):e004229. doi: 10.1161/CIRCEP.116.004229.
citation: Peretto G, Busnardo E, Ferro P, Palmisano A, Vignale D, Esposito A, De Luca G, Campochiaro C, Sartorelli S, De Gaspari M, Rizzo S, Dagna L, Basso C, Gianolli L, Della Bella P, Sala S. Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis. JACC Cardiovasc Imaging. 2022 Oct;15(10):1771-1780. doi: 10.1016/j.jcmg.2022.02.029. Epub 2022 May 11.
citation: Peretto G, Sala S, Rizzo S, De Luca G, Campochiaro C, Sartorelli S, Benedetti G, Palmisano A, Esposito A, Tresoldi M, Thiene G, Basso C, Della Bella P. Arrhythmias in myocarditis: State of the art. Heart Rhythm. 2019 May;16(5):793-801. doi: 10.1016/j.hrthm.2018.11.024. Epub 2018 Nov 24.
citation: Wilde AAM, Semsarian C, Marquez MF, Sepehri Shamloo A, Ackerman MJ, Ashley EA, Sternick EB, Barajas-Martinez H, Behr ER, Bezzina CR, Breckpot J, Charron P, Chockalingam P, Crotti L, Gollob MH, Lubitz S, Makita N, Ohno S, Ortiz-Genga M, Sacilotto L, Schulze-Bahr E, Shimizu W, Sotoodehnia N, Tadros R, Ware JS, Winlaw DS, Kaufman ES; Document Reviewers; Aiba T, Bollmann A, Choi JI, Dalal A, Darrieux F, Giudicessi J, Guerchicoff M, Hong K, Krahn AD, MacIntyre C, Mackall JA, Mont L, Napolitano C, Ochoa JP, Peichl P, Pereira AC, Schwartz PJ, Skinner J, Stellbrink C, Tfelt-Hansen J, Deneke T. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022 Jul;19(7):e1-e60. doi: 10.1016/j.hrthm.2022.03.1225. Epub 2022 Apr 4. No abstract available.
citation: Peretto G, Sala S, Basso C, Rizzo S, Radinovic A, Frontera A, Limite LR, Paglino G, Bisceglia C, De Luca G, Campochiaro C, Sartorelli S, Palmisano A, Esposito A, Busnardo E, Villatore A, Baratto F, Cireddu M, Marzi A, D'Angelo G, Gulletta S, Vergara P, De Cobelli F, Dagna L, Mazzone P, Della Bella P. Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis. J Am Coll Cardiol. 2020 Oct 6;76(14):1644-1656. doi: 10.1016/j.jacc.2020.08.012.
citation: Peretto G, Sala S, De Luca G, Marcolongo R, Campochiaro C, Sartorelli S, Tresoldi M, Foppoli L, Palmisano A, Esposito A, De Cobelli F, Rizzo S, Thiene G, Basso C, Dagna L, Caforio ALP, Della Bella P. Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. JACC Clin Electrophysiol. 2020 Oct;6(10):1221-1234. doi: 10.1016/j.jacep.2020.05.013. Epub 2020 Jun 24.
citation: Peretto G, Mazzone P, Paglino G, Marzi A, Tsitsinakis G, Rizzo S, Basso C, Della Bella P, Sala S. Continuous Electrical Monitoring in Patients with Arrhythmic Myocarditis: Insights from a Referral Center. J Clin Med. 2021 Nov 1;10(21):5142. doi: 10.3390/jcm10215142.
citation: Peretto G, Sala S, Rizzo S, Palmisano A, Esposito A, De Cobelli F, Campochiaro C, De Luca G, Foppoli L, Dagna L, Thiene G, Basso C, Della Bella P. Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation. J Am Coll Cardiol. 2020 Mar 10;75(9):1046-1057. doi: 10.1016/j.jacc.2020.01.036.
citation: Peretto G, Barzaghi F, Cicalese MP, Di Resta C, Slavich M, Benedetti S, Giangiobbe S, Rizzo S, Palmisano A, Esposito A, De Cobelli F, Gulletta S, Basso C, Casari G, Aiuti A, Della Bella P, Sala S. Immunosuppressive therapy in childhood-onset arrhythmogenic inflammatory cardiomyopathy. Pacing Clin Electrophysiol. 2021 Mar;44(3):552-556. doi: 10.1111/pace.14153. Epub 2021 Jan 18.
citation: Asatryan B, Asimaki A, Landstrom AP, Khanji MY, Odening KE, Cooper LT, Marchlinski FE, Gelzer AR, Semsarian C, Reichlin T, Owens AT, Chahal CAA. Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review. Circulation. 2021 Nov 16;144(20):1646-1655. doi: 10.1161/CIRCULATIONAHA.121.055890. Epub 2021 Nov 15.
citation: Peretto G, Sommariva E, Di Resta C, Rabino M, Villatore A, Lazzeroni D, Sala S, Pompilio G, Cooper LT. Myocardial Inflammation as a Manifestation of Genetic Cardiomyopathies: From Bedside to the Bench. Biomolecules. 2023 Apr 4;13(4):646. doi: 10.3390/biom13040646.
citation: Ammirati E, Raimondi F, Piriou N, Sardo Infirri L, Mohiddin SA, Mazzanti A, Shenoy C, Cavallari UA, Imazio M, Aquaro GD, Olivotto I, Pedrotti P, Sekhri N, Van de Heyning CM, Broeckx G, Peretto G, Guttmann O, Dellegrottaglie S, Scatteia A, Gentile P, Merlo M, Goldberg RI, Reyentovich A, Sciamanna C, Klaassen S, Poller W, Trankle CR, Abbate A, Keren A, Horowitz-Cederboim S, Cadrin-Tourigny J, Tadros R, Annoni GA, Bonoldi E, Toquet C, Marteau L, Probst V, Trochu JN, Kissopoulou A, Grosu A, Kukavica D, Trancuccio A, Gil C, Tini G, Pedrazzini M, Torchio M, Sinagra G, Gimeno JR, Bernasconi D, Valsecchi MG, Klingel K, Adler ED, Camici PG, Cooper LT Jr. Acute Myocarditis Associated With Desmosomal Gene Variants. JACC Heart Fail. 2022 Oct;10(10):714-727. doi: 10.1016/j.jchf.2022.06.013. Epub 2022 Sep 7.
citation: Piriou N, Marteau L, Kyndt F, Serfaty JM, Toquet C, Le Gloan L, Warin-Fresse K, Guijarro D, Le Tourneau T, Conan E, Thollet A, Probst V, Trochu JN. Familial screening in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardiomyopathies. ESC Heart Fail. 2020 Aug;7(4):1520-1533. doi: 10.1002/ehf2.12686. Epub 2020 May 1.
citation: Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, Sanchez-Munoz JJ, Oliva-Sandoval MJ, Gimeno JR. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015 Apr;12(4):766-73. doi: 10.1016/j.hrthm.2015.01.001. Epub 2015 Jan 20.
citation: Peretto G, Mazzone P. Arrhythmogenic Cardiomyopathy: One, None and a Hundred Thousand Diseases. J Pers Med. 2022 Jul 30;12(8):1256. doi: 10.3390/jpm12081256.
citation: Peretto G, De Luca G, Villatore A, Di Resta C, Sala S, Palmisano A, Vignale D, Campochiaro C, Lazzeroni D, De Gaspari M, Rizzo S, Busnardo E, Ferro P, Gianolli L, Basso C, Dagna L, Esposito A, Benedetti S, Della Bella P. Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report. JACC Basic Transl Sci. 2023 Jul 5;8(7):755-765. doi: 10.1016/j.jacbts.2023.02.018. eCollection 2023 Jul.
citation: Peretto G, Sala S, Della Bella P, Basso C, Cooper LT Jr. Reply: Genetic Basis for Acute Myocarditis Presenting With Ventricular Arrhythmias? J Am Coll Cardiol. 2020 Jul 7;76(1):126-128. doi: 10.1016/j.jacc.2020.05.014. No abstract available.
citation: Peretto G, Casella M, Merlo M, Benedetti S, Rizzo S, Cappelletto C, Di Resta C, Compagnucci P, De Gaspari M, Dello Russo A, Casari G, Basso C, Sala S, Sinagra G, Della Bella P, Cooper LT Jr. Inflammation on Endomyocardial Biopsy Predicts Risk of MACE in Undefined Left Ventricular Arrhythmogenic Cardiomyopathy. JACC Clin Electrophysiol. 2023 Jul;9(7 Pt 1):951-961. doi: 10.1016/j.jacep.2022.10.032. Epub 2023 Jan 18.
citation: Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, Bohm M, Charron P, Elliott PM, Eriksson U, Felix SB, Garcia-Pavia P, Hachulla E, Heymans S, Imazio M, Klingel K, Marcolongo R, Matucci Cerinic M, Pantazis A, Plein S, Poli V, Rigopoulos A, Seferovic P, Shoenfeld Y, Zamorano JL, Linhart A. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017 Sep 14;38(35):2649-2662. doi: 10.1093/eurheartj/ehx321. No abstract available.
citation: Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006 Apr 11;113(14):1807-16. doi: 10.1161/CIRCULATIONAHA.106.174287. Epub 2006 Mar 27.
citation: Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008 Jan;29(2):270-6. doi: 10.1093/eurheartj/ehm342. Epub 2007 Oct 4.
citation: Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018 Oct;15(10):e190-e252. doi: 10.1016/j.hrthm.2017.10.035. Epub 2017 Oct 30. No abstract available.
citation: Tfelt-Hansen J, Winkel BG, de Riva M, Zeppenfeld K. The '10 commandments' for the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2023 Jan 14;44(3):176-177. doi: 10.1093/eurheartj/ehac699. No abstract available.